Work

A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second relapse: An international collaborative group trial of ANZGOG and HOG.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.tps5612

Authors: Danny Rischin, Daniela Matei, Jeffrey C. Goh, Michelle Margaret Vaughan, Philip James Beale, Meaghan Elizabeth Tenney, Julie Martyn, Dirkje Willemien Sommeijer, Jose Luis Iglesias, David C. Bibby, Jeremy Simpson, Elizabeth E. Doolin, Corinne E. Williams, Martin R. Stockler, Australia New Zealand Gynaecological Oncology Group (ANZGOG)

Institutions: Peter MacCallum Cancer Centre, Indiana University School of Medicine, Royal Brisbane and Women's Hospital, Christchurch Hospital, University of Chicago Medical Center, The University of Sydney, Bionomics (Australia), Hoosier Cancer Research Network (United States)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2481799548

Cites:

Cited by:

Related to: 10